Super fast-acting insulin compositions
AssigneeHalozyme Therapeutics, Inc.
InventorsGregory I. Frost, Igor Bilinsky, Daniel Vaughn, Barry Sugarman
Life of this patent
Estimating the term…
Abstract
Provided are methods for control of post-prandial glucose in diabetic subjects by administering a fast-acting insulin analog and a hyaluronidase degrading enzyme. The fast-acting insulin analog and a hyaluronidase are administered between 15 minutes before the meal and 30 minutes after commencing the meal.
Claims23
A method for controlling post-prandial glucose levels in a subject, comprising administering to the subject a fast-acting insulin analog and a hyaluronan-degrading enzyme less than 15 minutes before a meal up until 30 minutes after commencing a meal, wherein:
- the amount hyaluronidase administered is sufficient to render the fast-acting insulin analog a super fast acting insulin;
- a super fast-acting insulin has an onset of action that is faster than the analog alone, and a duration of action that is shorter than the analog alone, whereby, upon administration, the super fast-acting insulin closely mimics the physiologic post-prandial insulin response of a non-diabetic subject to achieve post-prandial glycemic control;
- the sufficient amount of a hyaluronan degrading enzyme to render the a super fast-acting insulin composition is 1 Unit or more hyaluronidase activity/mL;
- and
- administration of the fast-acting insulin analog and the hyaluronidase degrading enzyme is effected via subcutaneous, intradermal, intramuscular or intraperitoneal administration.
Dependencies are inferred from the claim text.